Novavax (NVAX) experienced a notable uptick in its stock price Friday, climbing roughly 13% as investors reacted positively to the company's first-quarter financial results. The vaccine developer reported revenue of $139.5 million, surpassing analyst expectations of $78.3 million, according to LSEG data. The stock traded at $10.45 with volume exceeding 8.4 million shares, reflecting heightened market interest.
Revenue Boost from Licensing Deals
The quarterly performance was largely driven by licensing and partner payments, which provided a buffer against continued weak demand for COVID-19 vaccines. Licensing, royalties, and other revenue climbed to $97 million, including $30 million from Pfizer's January deal for a non-exclusive license to Novavax's Matrix-M adjuvant. This adjuvant is designed to enhance immune response in vaccines, and Pfizer has secured rights for two infectious disease indications. The deal includes potential milestone payments of up to $500 million, plus royalties.
Strategic Pivot to Partnership Model
CEO John Jacobs highlighted during the analyst call that Novavax's strategy of licensing its technology and forming early-stage partnerships insulates the company from shifting policy risks. By not taking products through late-stage trials and commercialization alone, Novavax avoids significant financial exposure. Jacobs noted strong demand for Matrix-M, with partners now holding rights to explore its use in over 30 areas spanning infectious diseases and cancer.
Sanofi Partnership and Competitive Edge
Sanofi remains a key partner, with Novavax relying on the French company's efforts around Nuvaxovid and a COVID-flu combo shot to achieve profitability by 2028. Last month, Sanofi reported that Nuvaxovid outperformed Moderna's mNEXSPIKE on tolerability in a Phase 4 study of 1,000 adults, measuring common side effects like fever and fatigue.
Pipeline Developments
Novavax also provided updates on early-stage projects. The company announced a vaccine candidate targeting C. difficile, a bacterial infection causing severe diarrhea and colitis, could enter human trials as early as 2027. Chief strategy officer Elaine O'Hara estimated the market potential at $1.5 billion to $2.5 billion, assuming competitors also enter the space.
Financial Health and Risks
Despite the positive revenue beat, Novavax reported a first-quarter net loss of $9.5 million, and Nuvaxovid sales were just $10 million. The company continues to rely heavily on the Serum Institute of India for co-formulation and finishing of its COVID-19 shot. Any disruption with this partner, weaker demand, or policy changes could jeopardize the 2028 profitability target. Novavax maintained its 2026 adjusted revenue guidance of $230 million to $270 million, excluding certain Sanofi-related sales. As of March 31, the company held $795 million in cash and marketable securities.
Upcoming Investor Event
Investors will get another look at the company next week when Novavax participates in a BofA Securities health-care fireside chat in Las Vegas on May 13, with investor meetings also scheduled. This event could provide further clarity on the company's strategic direction and pipeline progress.
